Compare FEMY & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | LTRN |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 31.5M |
| IPO Year | 2021 | 2020 |
| Metric | FEMY | LTRN |
|---|---|---|
| Price | $0.50 | $2.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 442.0K | 48.0K |
| Earning Date | 05-07-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.60 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,629,108.00 | N/A |
| Revenue This Year | $59.47 | N/A |
| Revenue Next Year | $150.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 51.97 | N/A |
| 52 Week Low | $0.31 | $2.03 |
| 52 Week High | $1.63 | $5.74 |
| Indicator | FEMY | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 31.23 |
| Support Level | $0.48 | N/A |
| Resistance Level | $0.58 | $3.65 |
| Average True Range (ATR) | 0.04 | 0.17 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 12.87 | 20.73 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.